![Datopotamab deruxtecan vs docetaxel for previously treated advanced NSCLC](https://oncodaily.com/pub/uploads/2024/09/tropion.png)
Photo from clinicaloptions.com
Sep 12, 2024, 09:48
Datopotamab deruxtecan vs docetaxel for previously treated advanced NSCLC
Erman Akkus shared a post on X about a recent paper by Myung-Ju Ahn et al. published in JCO.
Authors: Myung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares, Aaron Lisberg, Jacob Sands et al.
“Datopotamab deruxtecan vs docetaxel for previously treated advanced NSCLC.
TROPION-Lung01
- Improved PFS in nonsquamous histology
5.5 vs3.6 mo, HR: 0.63 (0.51-0.79) - Not OS
- Not PFS or OS in squamous histology.”
Source: Erman Akkus/X
Erman Akkus is a medical oncology fellow at the Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education from the Medical University of Vienna.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 12, 2024, 09:48
Sep 12, 2024, 09:43
Sep 12, 2024, 09:40
Sep 12, 2024, 09:36
Sep 12, 2024, 09:24
Sep 12, 2024, 09:19